These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. A guide to drug use during percutaneous coronary intervention. Choo JK; Young JJ; Kereiakes DJ Drugs; 2002; 62(18):2589-601. PubMed ID: 12465999 [TBL] [Abstract][Full Text] [Related]
7. Direct thrombin inhibitors for percutaneous coronary intervention in the current era of platelet glycoprotein IIb/IIIa inhibition. Reginelli JP; Chew D J Interv Cardiol; 2002 Apr; 15(2):141-6. PubMed ID: 12063809 [No Abstract] [Full Text] [Related]
8. Direct thrombin inhibitors (part 2 of 2). Arora UK; Dhir M J Invasive Cardiol; 2005 Feb; 17(2):85-91. PubMed ID: 15687531 [No Abstract] [Full Text] [Related]
9. Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial). Chew DP; Lincoff AM; Gurm H; Wolski K; Cohen DJ; Henry T; Feit F; Topol EJ; Am J Cardiol; 2005 Mar; 95(5):581-5. PubMed ID: 15721095 [TBL] [Abstract][Full Text] [Related]
10. Current update on glycoprotein IIb-IIIa and direct thrombin inhibition in percutaneous coronary intervention for non-ST elevation acute coronary syndromes: balancing bleeding risk and antiplatelet efficacy. Kwa AT; Rogers JH J Interv Cardiol; 2008 Apr; 21(2):107-17. PubMed ID: 18248357 [TBL] [Abstract][Full Text] [Related]
11. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. Stone GW; Ware JH; Bertrand ME; Lincoff AM; Moses JW; Ohman EM; White HD; Feit F; Colombo A; McLaurin BT; Cox DA; Manoukian SV; Fahy M; Clayton TC; Mehran R; Pocock SJ; JAMA; 2007 Dec; 298(21):2497-506. PubMed ID: 18056903 [TBL] [Abstract][Full Text] [Related]
13. The benefits of platelet glycoprotein IIb/IIIa receptor inhibition during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: drug-specific or class effect? Brener SJ J Am Coll Cardiol; 2009 May; 53(18):1674-6. PubMed ID: 19406343 [No Abstract] [Full Text] [Related]
14. Updated guidelines for percutaneous coronary intervention: what are the most important changes? Spencer BK; Smith SC Pol Arch Med Wewn; 2008 Mar; 118(3):96-7. PubMed ID: 18476453 [No Abstract] [Full Text] [Related]
15. [Advances in adjunctive pharmacological therapy for percutaneous coronary interventions]. Benito B; Masotti M; Betriu A Rev Esp Cardiol; 2005 Jun; 58(6):729-43. PubMed ID: 15970124 [TBL] [Abstract][Full Text] [Related]
16. Long-term impact of chronic kidney disease in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. Saltzman AJ; Stone GW; Claessen BE; Narula A; Leon-Reyes S; Weisz G; Brodie B; Witzenbichler B; Guagliumi G; Kornowski R; Dudek D; Metzger DC; Lansky AJ; Nikolsky E; Dangas GD; Mehran R JACC Cardiovasc Interv; 2011 Sep; 4(9):1011-9. PubMed ID: 21939942 [TBL] [Abstract][Full Text] [Related]
17. Advances in percutaneous coronary intervention in patients with chronic kidney disease. Coats WC; Dellsperger KC Adv Perit Dial; 2010; 26():42-6. PubMed ID: 21348378 [TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamic and clinical trials of glycoprotein IIb/IIIa inhibitors and potential relationship of results to dosing. Hobbach HP; Schuster P Z Kardiol; 2003 Mar; 92(3):213-8. PubMed ID: 12658467 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]